BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
- and NESS ZIONA, Israel, April 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
- Initial top line results of the Phase 2 trial are expected in the first quarter of 2025.
- However, our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
- ET to discuss its fourth quarter and full year 2023 financial results and to provide a corporate update.